Bayer has officially introduced Centafore, its new Imaging Core Lab, to offer imaging services for clinical trials and Software as a Medical Device (SaMD) development. With over 25 years of in-house experience supporting more than 200 studies, the service is now available to external partners. The lab specializes in image management, analysis, and interpretation for clinical research, with a strong team that includes radiologists and imaging professionals. Nelson Ambrogio, President of Radiology at Bayer, commented, “By leveraging our extensive experience and expertise, we are dedicated to providing our customers with high-quality imaging services that meet their specific needs in clinical research. Through Centafore, we aim to enhance the reliability of trial outcomes and support informed decision-making in the development of investigational medicines, ultimately benefiting patients and improving their quality of care.”
Centafore supports a wide range of medical fields, including oncology, neurology, cardiology, pediatrics, and dermatology, offering imaging services from early research through late-phase clinical trials. As an Imaging Contract Research Organization (iCRO), it helps pharmaceutical, biotech, medical device, and digital health companies meet regulatory and data privacy requirements. Bayer’s collaboration with Centafore alongside its ongoing partnerships with organizations such as OBIO and Luxsonic Technologies reinforces its commitment to advancing healthcare innovation. With a long-standing focus on diagnostic imaging, Bayer brings a comprehensive radiology portfolio including contrast agents, imaging devices and digital tools to support clinical development. This initiative further strengthens Bayer’s position in the imaging space and contributes to more reliable trial outcomes and improved patient care.
